Addition of lomustine for bevacizumab-refractory recurrent glioblastoma

Authors

  • Michaela Tonder Department of Neurology, University Hospital Zurich, Zurich, Switzerland
  • Günter Eisele Department of Neurology, University Hospital Zurich, Zurich, Switzerland
  • Tobias Weiss Department of Neurology, University Hospital Zurich, Zurich, Switzerland
  • Silvia Hofer Department of Oncology University Hospital Zurich, Zurich, Switzerland
  • Katharina Seystahl Department of Neurology, University Hospital Zurich, Zurich, Switzerland
  • Antonios Valavanis Institute of Neuroradiology, University Hospital Zurich, Zurich, Switzerland
  • Roger Stupp Department of Oncology University Hospital Zurich, Zurich, Switzerland
  • Michael Weller Department of Neurology, University Hospital Zurich, Zurich, Switzerland
  • Patrick Roth Department of Neurology, University Hospital Zurich, Zurich, Switzerland

DOI:

https://doi.org/10.3109/0284186X.2014.920960

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2014-10-01

How to Cite

Tonder, M., Eisele, G., Weiss, T., Hofer, S., Seystahl, K., Valavanis, A., … Roth, P. (2014). Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. Acta Oncologica, 53(10), 1436–1440. https://doi.org/10.3109/0284186X.2014.920960

Issue

Vol. 53 No. 10 (2014): Acta Oncologica

Section

Articles